State of the Art in BRCA-Mutated Ovarian Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Ovarian Cancer

Case 1 Susan

Case 1 Susan (cont)

Frequency of Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer

Genetic Testing of Ovarian Cancer

Mutation Status by Histology

Single-Gene vs Multigene (Panel) Testing

Cascade Testing and Genetic Counseling

Genetic Testing Rates

Effect of BRCA Mutations in the Front Line

Germline vs Somatic Mutations

Case 2 Angela

Case 2 Angela (cont)

FDA-Approved PARP Inhibitors

Phase 3 PARP Inhibitor Maintenance Studies

PFS in Phase 3 Maintenance Studies

Maintenance Studies Patients in PR vs CR

PFS Hazard Ratio by Mutation Status

Case 2 Angela (cont)

PARP Inhibitors Safety

Toxicity GI and Fatigue

Toxicity Hematologic

Toxicity Other

Future Directions

Key Takeaways

Abbreviations

Abbreviations (cont)